



an Open Access Journal by MDPI

Hippo Signaling in Cancer

Guest Editors:

Dr. Ying Yan

Department of Radiation
Oncology, College of Medicine,
University of Nebraska Medical
Center, Omaha, NE, USA

Prof. Dr. Michel Ouellette

Department of Internal Medicine,
College of Medicine, University of
Nebraska Medical Center,
Omaha, NE, USA

Deadline for manuscript
submissions:

closed (20 February 2024)

Message from the Guest Editors

Dear Colleagues,

This Special Issue in *Cancers* aims to present the current achievements of scientific investigations focusing on Hippo signaling, with emphasis on oncogenesis, cancer progression, metastasis, cancer therapy resistance, and the development of targeted anticancer agents based on Hippo signaling. The topic is of particular importance because the dysregulation of Hippo signaling occurs in many types of human cancer and contributes to cancer development, progression, metastasis, and therapeutic resistance. Recent advances in methods and technologies of cell biology, molecular biology, immunology, and biochemistry have enabled fast growth in this area. This Special Issue aims to present the most important recent achievements in this unique field of cancer research.

Dr. Ying Yan

Prof. Dr. Michel Ouellette

Guest Editors



mdpi.com/si/147424

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)